



For immediate release

**LEADING PERFORMANCE-ENHANCING DRUG RESEARCH INSTITUTE
ANTI-DOPING RESEARCH (ADR) ESTABLISHES NONPROFIT STATUS**

(Los Angeles, June 24, 2008) -- Anti-Doping Research, Inc. (ADR), one of the world's leading scientific institutes battling the use of performance-enhancing drugs in sport, is pleased to announce that it has achieved legal status as a nonprofit entity.

"We've been up and running and fully-operational for awhile now," says Dr. Don Catlin, a founder and Chief Executive Officer of the organization. "But now it's all official and we're thrilled, because others can now join us in our mission to help rid sport of performance-enhancing drugs."

ADR's new status as a public charity will allow its contributors to claim a tax deduction for their donations. ADR is also developing innovative programs for athletes, organizations and the general public to get involved in the battle against doping in sport and help make a difference.

Founded in 2005, ADR is considered one of the world's most renowned performance-enhancing drug research organizations. Its mission is to help rid sport of performance-enhancing drugs by, among other means, identifying new drugs being used in competition and developing the tests to detect them.

Catlin is widely considered one of the fathers of drug testing in sport. He previously founded the first anti-doping lab in the United States, the UCLA Olympic Analytical Laboratory, and served as its director for 25 years. He has overseen the drug testing of sports at every level, including Olympic, professional and collegiate, and he and his team of top researchers have been instrumental in pioneering identification techniques for many performance-enhancing drugs, including artificial testosterone, the blood booster darbepoetin, and the designer steroid THG or "The Clear."

Events such as the BALCO investigation solidified Catlin and his colleagues' realization that research and testing development needed to be bolstered and made permanent.

"We saw that continuing the battle against performance-enhancing drugs in sport meant taking our work to the next level and devoting our efforts to keeping up with the introduction of new, old and ever-evolving performance-enhancing drugs," he said.

Among ADR's current priorities is developing a reliable urine test to detect the use of human growth hormone (hGH), an important goal for many sports groups worldwide. Additionally,



ADR is working with thoroughbred racing to assist in the development of new testing approaches and techniques for the industry.

In addition to creating new methods and improving old methods to detect performance-enhancing drugs, ADR seeks to foster education about doping and its consequences and help initiate positive programs that encourage competitors of all ages and levels to stay clean. ADR also is working to develop effective collaboration in this important field.

Major contributors to ADR include Amgen, the Grayson-Jockey Club Research Foundation/Equine Drug Research Institute, Major League Baseball, the National Football League/NFL Players Association Research and Education Foundation, and the United States Anti-Doping Agency.

“ADR is excited to begin offering athletes, organizations and the general public new ways to participate in the battle against performance-enhancing drugs.” says Oliver Catlin, ADR’s Vice President and Chief Financial Officer and an ADR founder. “In addition to making it easier for individuals and organizations to contribute financially, we are creating new and exciting opportunities for those who care about drug-free sport to get more involved and help make a difference.”

For more information on ADR and its activities, visit ADR’s newly revamped website at www.antidopingresearch.org.

###

Contacts:

Joseph Taylor
Public Relations Consultant
jtaylor@antidopingresearch.org

Oliver Catlin
Vice President & CFO
octalin@antidopingresearch.org

310-482-6925 (Office)